Clinical Outcomes of First-Time and Redo Mitral Valve Replacement Using MITRIS RESILIA Bioprosthesis

Q: What are the key findings of this study?

Mitral valve replacement using the MITRIS RESILIA bioprosthesis was associated with low perioperative mortality, favorable safety, and durable hemodynamic performance (P < 0.001).

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Mitral valve disease (n=140). Intervention: MITRIS RESILIA bioprosthesis.

Q: What question did this study set out to answer?

To assess the clinical safety, perioperative outcomes, and hemodynamic performance of the MITRIS RESILIA bioprosthesis in both first-time and redo mitral valve replacement.

Satoshi Kainuma; Tomoki Shimokawa; Tomohiro Iwakura; Haruki Mikoshiba; Atsushi Yano; Atsushi Kurushima; Tatsuo Motoki; Yoshiaki Fukumura; Kazuhisa Sakamoto; Yuki Wada; Nobuhisa Ohno; Tomoki Ushijima; Akira Shiose; Katsuhiro Omae; Manabu Minami; Kuniya Asai; Rieko Kutsuzawa; Shinya Tajima; Tomoyuki Fujita; Satsuki Fukushima

doi:10.1016/j.atssr.2025.12.015

Key result

MITRIS RESILIA bioprosthesis links to low perioperative mortality and durable hemodynamics in mitral valve replacement.

P<.001
n=140

Figures

Why the study?

Clinical data on the safety and hemodynamic performance of the MITRIS RESILIA bioprosthetic mitral valve remain limited.

Does mitral valve replacement with the MITRIS RESILIA bioprosthesis provide favorable safety and hemodynamic performance in patients requiring first-time or redo MVR?

Key Points

To assess the clinical safety, perioperative outcomes, and hemodynamic performance of the MITRIS RESILIA bioprosthesis in both first-time and redo mitral valve replacement.
Retrospective multicenter study of 140 patients (mean age, 75 ± 8 years; 44% male) who underwent first-time (n = 100) or redo (n = 40) mitral valve replacement between 2021 and 2022.
Primary indications were mitral regurgitation and stenosis for primary procedures, and prosthetic valve dysfunction or failed repair for redo procedures, with a mean follow-up of 36 ± 14 months (415 patient-years).
First-time and redo replacements with the bioprosthetic valve achieved low perioperative mortality and a favorable overall safety profile over a mean 36-month follow-up.
The valve demonstrated durable hemodynamic performance across all procedural indications (P < .001).

Study Design

Type

Cohort (n=140)

Multicenter

Yes

Structured PICO

Does mitral valve replacement with the MITRIS RESILIA bioprosthesis provide favorable safety and hemodynamic performance in patients requiring first-time or redo MVR?

P

Population

140 patients (mean age 75 years, 56% female) undergoing first-time or redo mitral valve replacement with a MITRIS RESILIA valve, followed for a mean of 36 months.

E

Exposure

Mitral valve replacement (MVR) using the MITRIS RESILIA bioprosthesis

O

Outcome

Safety (perioperative mortality) and hemodynamic performancesafety

Main Result

p-value: p=< .001

Implication

The MITRIS RESILIA bioprosthesis demonstrates favorable safety and durable hemodynamic performance for both first-time and redo mitral valve replacement.

Abstract

Background: The MITRIS RESILIA bioprosthetic valve incorporates anticalcification technology and is designed to facilitate implantation in fragile mitral annuli. However, clinical data on its safety and hemodynamic performance remain limited. Methods: We conducted a retrospective multicenter study of 140 patients (mean age, 75 ± 8 years; 44% male) who underwent first-time (n = 100) or redo (n = 40) mitral valve replacement (MVR) with a MITRIS RESILIA valve between 2021 and 2022. The primary indication for first-time MVR was mitral regurgitation, followed by mitral stenosis, whereas that for redo MVR was prosthetic valve dysfunction, followed by failed repair. The mean follow-up duration was 36 ± 14 months (415 patient-years). Results: < .001). Conclusions: First-time and redo MVR with the MITRIS RESILIA valve was associated with low perioperative mortality, favorable safety, and durable hemodynamic performance. These findings support its use across a broad spectrum of mitral valve diseases.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kainuma et al. (2026) conducted a cohort in Mitral valve disease (n=140). MITRIS RESILIA bioprosthesis was evaluated (p=< .001). Mitral valve replacement using the MITRIS RESILIA bioprosthesis was associated with low perioperative mortality, favorable safety, and durable hemodynamic performance (P < 0.001).

synapsesocial.com/papers/6963220591e05aa366cb8675 https://doi.org/10.1016/j.atssr.2025.12.015

View Full Paper

Ask AI

Bookmark

Share

Clinical Outcomes of First-Time and Redo Mitral Valve Replacement Using MITRIS RESILIA Bioprosthesis

Figures

Key Points

Study Design

Structured PICO

Main Result

Implication

Abstract

Discussion

Cite This Study

Clinical Outcomes of First-Time and Redo Mitral Valve Replacement Using MITRIS RESILIA Bioprosthesis

Figures

Key Points

Study Design

Structured PICO

Main Result

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Annals of Thoracic Surgery Short Reports

Keep reading

More related papers

More from Annals of Thoracic Surgery Short Reports